Surfing the MASH Tsunami
Episodes
S3-E60.3 - Madrigal Announcement on Resmetirom: Diving into Implications
24 Dec 2022
Contributed by Lukas
Send a textIn a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced posit...
S3-E60.2 - Madrigal Announcement on Resmetirom: First Reactions and Differing Perspectives
24 Dec 2022
Contributed by Lukas
Send a textIn a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced posit...
S3-E60.1 - Donna Cryer on the Far-Reaching Implications of Madrigal’s Emerging Story on Resmetirom
24 Dec 2022
Contributed by Lukas
Send a textIn a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced posit...
S3-E61 - NASH-TAG 2023 Preview with Stephen Harrison
23 Dec 2022
Contributed by Lukas
Send a textNASH-TAG 2023 co-course director Stephen Harrison and scientific advisory board committee member Jörn Schattenberg join Louise Campbell an...
S3-E60 - Madrigal Announces Breaking News: Positive Topline Results from Pivotal MAESTRO-NASH Trial of Resmetirom
21 Dec 2022
Contributed by Lukas
Send a textYesterday, in a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals anno...
S3-E59.3 - Year-End Interview with Donna Cryer
18 Dec 2022
Contributed by Lukas
Send a textIn another exciting installment of the Surfing NASH year-end interview series, Jörn Schattenberg, Louise Campbell and Roger Green are join...
S3- E59.2 - Year-End Interview with Hannes Hagström
17 Dec 2022
Contributed by Lukas
Send a textIn this exclusive interview, Hannes Hagström joins Jörn Schattenberg, Louise Campbell and Roger Green to explore papers emerging from Sca...
S3-E59.1 - Year-End Interview with Scott Friedman
17 Dec 2022
Contributed by Lukas
Send a textIn the Season 3 NAFLD Year-in-Review conversations series, Surfers Jörn Schattenberg, Louise Campbell and Roger Green embark on a string...
S3-E59 - 2022 NAFLD Year-in-Review Interview Series, Part 1
15 Dec 2022
Contributed by Lukas
Send a textThe latter half of December marks the Surfing the NASH Tsunami annual NAFLD Year-in-Review. In Part 1 of this Season 3 finale, Surfers Jör...
S3-58.5 - From the Vault: Part 2: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.com
11 Dec 2022
Contributed by Lukas
Send a textThis week, our conversation From the Vault features a special, single-interview episode to give listeners a chance to learn about Jörn Sch...
S3-58.4 - From the Vault: Part 1: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.com
11 Dec 2022
Contributed by Lukas
Send a textThis week, our conversation From the Vault features a special, single-interview episode to give listeners a chance to learn about Jörn Sc...
S3-E58.3 - NAIL-NIT Retrospective Analysis and the Role of Consortia in Reshaping the Focus of NITs
10 Dec 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami begins its year-end series to reflect on a momentous 2022 for NAFLD and Season 3 of the podcast. Leading this fina...
S3-E58.2 - Expanding Benefits in FibroScan Use and Integrating Digital Tools
10 Dec 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami begins its year-end series to reflect on a momentous 2022 for NAFLD and Season 3 of the podcast. In this conversat...
S3-E58.1 - Returning to In-Person Meetings and Emerging News on NICE and FibroScan
10 Dec 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami begins its year-end series to reflect on a momentous 2022 for NAFLD and Season 3 of the podcast. In this conversat...
S3-E58 - Surfing 2022: NAFLD Year-in-Review
08 Dec 2022
Contributed by Lukas
Send a textSurfers Jörn Schattenberg, Louise Campbell and Roger Green host the Season 3, Year-in-Review episode to reflect on major themes and takeaw...
S3-E57.5 - From the Vault: “Seeing what Should Be” – Imaging the Liver To Assess Functioning Hepatocytes
04 Dec 2022
Contributed by Lukas
Send a textLars Johannson’s 2021 Paris NASH presentation, “Innovations in Imaging Assessment of Fibrosis“,” introduced his audience to a dynam...
S3-E57.4 - Discussing Critical Success Factors for Placebo Cohorts
04 Dec 2022
Contributed by Lukas
Send a textThe Liver Forum aims to advance the regulatory sciences for the treatment of NAFLD/NASH and liver fibrosis by providing a neutral, independ...
S3-E57.3 - A Priori Placebo Response Rates and Challenges in Managing Samples Through Trials
03 Dec 2022
Contributed by Lukas
Send a textThe Liver Forum aims to advance the regulatory sciences for the treatment of NAFLD/NASH and liver fibrosis by providing a neutral, independ...
S3-E57.2 - Origins of the Liver Forum and Capturing the Richness of Data Emerging from NASH Studies
03 Dec 2022
Contributed by Lukas
Send a textPreviously, Executive Director Veronica Miller explained how she arrived to the field of NAFLD and the history of the Liver Forum. This con...
S3-E57.1 - Veronica Miller on Traversing from the HIV Forum to the Liver Forum
03 Dec 2022
Contributed by Lukas
Send a textThe Liver Forum aims to advance the regulatory sciences for the treatment of NAFLD/NASH and liver fibrosis by providing a neutral, independ...
S3-E57 - The Liver Forum: Fighting Fatty Liver Using Collective Knowledge and Experience
01 Dec 2022
Contributed by Lukas
Send a textThe Liver Forum aims to advance the regulatory sciences for the treatment of NAFLD/NASH and liver fibrosis by providing a neutral, independ...
S3-E56.6 - From the Vault: Focus On NASH Cirrhosis: Trials in Process and a Plea For MRE
27 Nov 2022
Contributed by Lukas
Send a textThis episode From the Vault follows Season 2, Episode 43 in discussing the possible role of NASH cirrhosis clinical trials in the transitio...
S3-E56.5 - Improving Patient Self-Management and Key Takeaways on Nutrition for NASH Resolution
27 Nov 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Alongsi...
S3-E56.4 - Integrated Solutions for Improved Patient Support
27 Nov 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing...
S3-E56.3 - The Psychology of Decision-Making Around Diet and Professional Support
26 Nov 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing...
S3-E56.2 - Setting and Driving Realistic Goals, and Dietician Visits as a Life-Long Therapy
26 Nov 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing...
S3-E56.1 - Weight Reduction for NASH Resolution: Strategies for Long-Term Adherence to Lifestyle Modifications
26 Nov 2022
Contributed by Lukas
Send a textSurfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing...
S3-E56 - Focus on the Intersection of Nutrition and NASH
24 Nov 2022
Contributed by Lukas
Send a textIn a timely debut during the American Thanksgiving holiday, Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NAS...
S3-E55.6 - From the Vault: #NASHDay 2022 Wrap-Up Panel: The Importance of #StopNASHNow
20 Nov 2022
Contributed by Lukas
Send a textThursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world’s largest liver patient advocac...
S3-E55.5 - Pediatric and Lean NASH: Learning from Diverse Populations
20 Nov 2022
Contributed by Lukas
Send a textGiven the vast amount of information and insight from The Liver Meeting, this episode sought to identify and explore a few key highlights. ...
S3-E55.4 - Emerging Roles for ELF Test and Advances in Use of PPARs
20 Nov 2022
Contributed by Lukas
Send a textGiven the vast amount of information and insight from The Liver Meeting, this episode sought to identify and explore a few key highlights. ...
S3-E55.3 - NIT Efficacy in Primary Care and Diabetes Clinic Settings
19 Nov 2022
Contributed by Lukas
Send a textGiven the vast amount of information and insight from The Liver Meeting, this episode sought to identify and explore a few key highlights. ...
S3-E55.2 - Comparing Global Health Systems, Standardizing AST and Educating on NAFLD Prevalence
19 Nov 2022
Contributed by Lukas
Send a textGiven the vast amount of information and insight from The Liver Meeting, this episode sought to identify and explore a few key highlights. ...
S3-E55.1 - Insights from Fatty Liver Foundation’s Annual Survey of Patient Perspectives
19 Nov 2022
Contributed by Lukas
Send a textGiven the vast amount of information and insight from The Liver Meeting, this episode sought to identify and explore a few key highlights. ...
S3-E55 - 2022 AASLD Wrap-Up: Reviewing a Momentous Meeting
17 Nov 2022
Contributed by Lukas
Send a textGiven the vast amount of information and insight from The Liver Meeting, this episode sought to identify and explore a few key highlights. ...
S3-E54.4 - An Interview with Michael Cooreman, CMO of Inventiva
13 Nov 2022
Contributed by Lukas
Send a textInventiva is a clinical-stage biopharmaceutical company that develops novel and differentiated oral small molecule therapies for patients s...
S3-E54.3 - Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study's Phase 3 Results
13 Nov 2022
Contributed by Lukas
Send a textOver 7,000 in-person attendees from around the world convened at the 73rd Annual AASLD Liver Meeting for a lively and momentous event in Wa...
S3-E54.2 - Presentation on Efruxifermin in NASH with Fibrosis
13 Nov 2022
Contributed by Lukas
Send a textLast month, Stephen Harrison joined the Surf to cover a recent string of press releases presaging some of the most promising data of the la...
S3-E54.1 - Utilizing Best Practices in Diagnostics
13 Nov 2022
Contributed by Lukas
Send a textSven Francque begins this conversation by discussing Laurent Castera’s paper comparing a range of NIT diagnostic tests: MAST, FAST, MEFIB...
S3-E53.3 - Pan-Society Presentation of NAFLD Nomenclature Consensus Process
12 Nov 2022
Contributed by Lukas
Send a textIn this conversation, Jeff McIntyre leads with his impressions on the pan-society presentation of NAFLD nomenclature consensus process. He ...
S3-E53.2 - Serum Metabolomics, Gene Therapy and the Waning Future of Biopsy
12 Nov 2022
Contributed by Lukas
Send a textRecorded onsite in Washington DC, Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green discuss takeaways from the first three d...
S3-E53.1 - The Gut Microbiome and Complexities of NAFLD
12 Nov 2022
Contributed by Lukas
Send a textRecorded onsite in Washington DC, Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green discuss takeaways from the first three d...
S3-E54 - AASLD 2022 Liver Meeting Live Coverage: Part 2
10 Nov 2022
Contributed by Lukas
Send a textThis week attendees from around the world convened at the 73rd Annual AASLD Liver Meeting for a lively and momentous event in Washington ...
S3-E53 - AASLD 2022 Liver Meeting Live Coverage: Part 1
07 Nov 2022
Contributed by Lukas
Send a textIn an insight-laden conversation recorded on site from Washington DC, Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green disc...
S3-E52.6 - From the Vault: AASLD 2021: The Path To Making NITs the “Gold Standard” for Drug Trials
06 Nov 2022
Contributed by Lukas
Send a textManal Abdelmalek, Jörn Schattenberg and Ian Rowe join Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related in...
S3-E52.5 - 2022 AASLD Preview: Final Thoughts
06 Nov 2022
Contributed by Lukas
Send a textIn a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green ...
S3-E52.4 - Exploring the NAFLD-Metabolic Link Through Screening Tools
06 Nov 2022
Contributed by Lukas
Send a textIn a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green ...
S3-E52.3 - Remote Wellness Tools and Disease Management
05 Nov 2022
Contributed by Lukas
Send a textIn a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green ...
S3-E52.2 - Efficacy of NITs and Predictive Outcomes
05 Nov 2022
Contributed by Lukas
Send a textIn a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green ...
S3-E52.1 - FIB-4 and the Way Forward in Primary Care Screening
05 Nov 2022
Contributed by Lukas
Send a textIn a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green ...
S3-E52 - Part 2: A Preview of the 2022 AASLD Liver Meeting
03 Nov 2022
Contributed by Lukas
Send a textIn a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green ...
S3-E51.5 - From the Vault: AASLD 2021 Wrap-up
30 Oct 2022
Contributed by Lukas
Send a textWhen AASLD announced that the 2021 event would be held as a purely virtual meeting, attendees and observers feared a loss of focus and the ...
S3-E51.4 - Discussing the NAFLD-Cancer Link and Fatty Liver Awareness
30 Oct 2022
Contributed by Lukas
Send a textThe 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington D...
S3-E51.3 - AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity
29 Oct 2022
Contributed by Lukas
Send a textThe 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington D...
S3-E51.2 - Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients
29 Oct 2022
Contributed by Lukas
Send a textThe 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington D...
S3-E51.1 - Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial
29 Oct 2022
Contributed by Lukas
Send a textThe 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington D...
S3-E51 - A Preview of the 2022 AASLD Liver Meeting
27 Oct 2022
Contributed by Lukas
Send a textThe 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington D...
S3-E50.6 - From the Vault: Digital Health and Patient Empowerment: a Conversation with Dr. Marcus Ranney
23 Oct 2022
Contributed by Lukas
Send a textOne of the most intriguing presentations at the inaugural Innovations in NAFLD Care 2022 conference (INCBCN) came from physician, author an...
S3-E50.5 - FIB-4 as a Front-Line Tool for Primary Care Triage
23 Oct 2022
Contributed by Lukas
Send a textOne critical success factor for putting a dent in Fatty Liver disease – one we do not discuss very often on the podcast – is patient em...
S3-E50.4 - Economics and Challenges of Pathway Design
23 Oct 2022
Contributed by Lukas
Send a textPatient empowerment can be an overlooked, yet critical success factor for putting a dent in Fatty Liver disease. In this conversation, the ...
S3-E50.3 - Patient Input for Clinical Care Pathways and Guidelines
22 Oct 2022
Contributed by Lukas
Send a textPatient empowerment can be an overlooked, yet critical success factor for putting a dent in Fatty Liver disease. This conversation details ...
S3-E50.2 - The Future of Digital Therapeutics and Patient Wellness Tools
22 Oct 2022
Contributed by Lukas
Send a textOne critical success factor for putting a dent in Fatty Liver disease – one we do not discuss very often on the podcast – is patient em...
S3-E50.1 - Patient Needs and Inputs for Trial Design
22 Oct 2022
Contributed by Lukas
Send a textOne critical success factor for putting a dent in Fatty Liver disease – one we do not discuss very often on the podcast – is patient em...
S3-E50 - Focus on Patient Advocacy
20 Oct 2022
Contributed by Lukas
Send a textOne critical success factor for putting a dent in Fatty Liver disease – one we do not discuss very often on the podcast – is patient em...
S3-E49.5 - From the Vault: The NICE Draft Guidance vs. The Economics of NAFLD: A Bad Fit
16 Oct 2022
Contributed by Lukas
Send a textThis conversation From the Vault comes from Season 3 Episode 13.4, part of NASH Tsunami’s coverage of the first NICE meeting on FibroScan...
S3-E49.4 - Delivering Meaningful Liver Test Results to Patients
16 Oct 2022
Contributed by Lukas
Send a textAmidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibra...
S3-E49.3 - Linking Liver Outcomes and Socioeconomic Status
15 Oct 2022
Contributed by Lukas
Send a textAmidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibra...
S3-E49.2 - Cancer vs Liver Disease Management: Political Pressures and Metaphorical Issues
15 Oct 2022
Contributed by Lukas
Send a textAmidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibra...
S3-E49.1 - NICE on FibroScan for Primary Care
15 Oct 2022
Contributed by Lukas
Send a textAmidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibra...
S3-E49 - NICE and VCTE Use in Community Settings
13 Oct 2022
Contributed by Lukas
Send a textAmidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibra...
S3-E48.6 - From the Vault: Themes From NASH-TAG 2022: Insights on Combination Therapies
09 Oct 2022
Contributed by Lukas
Send a textIn Season 3, Episode 6, Roger Green assembles audio clips from Surfing the NASH Tsunami’s coverage of NASH-TAG 2022 to reveal an evolving...
S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept
09 Oct 2022
Contributed by Lukas
Send a textA recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. This conv...
S3-E48.4 - Promising Interim Data from Axcella’s Phase 2B EMMPACT Study
09 Oct 2022
Contributed by Lukas
Send a textA recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this c...
S3-E48.3 - More Positive Phase 2B Results from Poxel
08 Oct 2022
Contributed by Lukas
Send a textA recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this c...
S3-E48.2 - Phase 2B 'Wow!' Results from Akero’s HARMONY Trial
08 Oct 2022
Contributed by Lukas
Send a textA recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this c...
S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide
08 Oct 2022
Contributed by Lukas
Send a textA recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this c...
S3-E48 - Review of Exciting Clinical Trial Press Releases
06 Oct 2022
Contributed by Lukas
Send a textA recent string of press releases has presaged some of the most exciting, promising data of the last decade in NASH drug development. In th...
S3-E47.6 - From the Vault: Most important Story of Summer: Ian Rowe says “FDA ELF Approval”
02 Oct 2022
Contributed by Lukas
Send a textIn this episode From the Vault, Surfers Roger Green and Louise Campbell are joined by Professor Ian Rowe to discuss the implications of the...
S3-E47.5 - Combination NIT Biomarkers and Developing a Viable System for Treating Patients
02 Oct 2022
Contributed by Lukas
Send a textAfter a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will...
S3-E47.4 - Potential Bottlenecks in Getting Drugs to NAFLD Patients
02 Oct 2022
Contributed by Lukas
Send a textAfter a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will...
S3-E47.3 - Implications of Positive Drug Trials and Eventual Approvals on NAFLD Treatment
01 Oct 2022
Contributed by Lukas
Send a textAfter a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will...
S3-E47.2 - The role of multiple biomarker tests in the diagnostic process
01 Oct 2022
Contributed by Lukas
Send a textAfter a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will...
S3-E47.1 - Collaborative energies shifting the force around Fatty Liver
01 Oct 2022
Contributed by Lukas
Send a textAfter a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will...
S3-E47 - What does the next year hold for the NAFLD-metabolic disease link?
29 Sep 2022
Contributed by Lukas
Send a textThe last month has witnessed several major Fatty Liver conferences and others that touch on NAFLD in the context of metabolic disease. One ...
S3-E46.6 - From the Vault: Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?
25 Sep 2022
Contributed by Lukas
Send a textThe 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. In Season 3, Episode 46, progra...
S3-E46.5 - Discussing NITs and Final Thoughts on NAFLD Summit
25 Sep 2022
Contributed by Lukas
Send a textThe 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. Program speakers Mazen Noureddi...
S3-E46.4 - Weight Change and Lifestyle Modification in Clinical Trials
25 Sep 2022
Contributed by Lukas
Send a textThe 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. Program speakers Mazen Noureddi...
S3 E46.3 - Discussing Clinical Trial Design at the NAFLD Summit
24 Sep 2022
Contributed by Lukas
Send a textThe 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. In this conversation, the panel...
S3-E46.2 - NAFLD Summit in Context and Learning from Failed Trials
24 Sep 2022
Contributed by Lukas
Send a textThe 2022 NAFLD Summit uniquely presented a range of perspectives and insights on fatty liver and metabolic diseases. Program speakers Mazen...
S3-E46.1 - Underreported Alcohol Use and Treating Comorbidities
24 Sep 2022
Contributed by Lukas
Send a textThe 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. Program speakers Mazen Noureddi...
S3-E46 - A Review of the 2022 NAFLD Summit from Dublin
22 Sep 2022
Contributed by Lukas
Send a textThe 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. In this episode, program speake...
S3-E45.5 - From the Vault: What Can NAIL-NIT Retrospective Analysis Tell Us About NASH?
20 Sep 2022
Contributed by Lukas
Send a textIn Season 3, Episode 19, the content focus looks at what the retrospective analysis from the NAIL-NIT consortium can achieve in terms of mo...
S3-E45.4 - Paris Review: NITs, Metabolic Disease and Final Thoughts
19 Sep 2022
Contributed by Lukas
Send a textIn this episode, the group covers the Day Two program and offers final thoughts on the Paris NASH 2022 review.The conversation starts with ...
S3-E45.3 - Paris Review: Session 5 on Clinical Trial Innovation
19 Sep 2022
Contributed by Lukas
Send a textThis episode addresses the other talks in Session 5 focusing on clinical trial innovation, after Frank Anania’s opener.Roy Sabo presented...
S3-E45.2 - Paris Review: Opening and Closing Sessions
19 Sep 2022
Contributed by Lukas
Send a textThe episode starts with Louise sounding an alarm about the rate of growth for cirrhosis and bridging or advanced cirrhosis. She is concerne...
S3 E45.1 - Paris Review: Regulator Response and "Dynamic Tension”
19 Sep 2022
Contributed by Lukas
Send a textThe episode begins with the panelists - Jörn, Louise, Jeff McIntyre of GLI and Roger - discussing one thing each found particularly striki...
S3-E45 - A Review of Paris NASH 2022 with Jeff McIntyre
15 Sep 2022
Contributed by Lukas
Send a textThe importance of integrating the NAFLD and NASH field within a wider scope of metabolic health was emphasized at the 8th Paris NASH Meetin...
S3-E44.6 - From Inside the Vault: Connecting the Dots at Paris NASH 2021
11 Sep 2022
Contributed by Lukas
Send a textThis week, Surfing the NASH Tsunami discusses a preview of the 8th Paris NASH Meeting taking place on September 8th & 9th, 2022. Paris ...
S3-E44.5 - Roger Green and Jeff Lazarus Discuss on NAFLD Summit
11 Sep 2022
Contributed by Lukas
Send a textRoger starts by asking Jeff to describe his role in the NAFLD Summit and to discuss any other presentations of interest outside of his own....
S3-E44.4 - Roger Green and Jeff Lazarus discuss NAFLD Nomenclature Conference and COVID-19
11 Sep 2022
Contributed by Lukas
Send a textRoger Green starts this interview with Jeff Lazarus by asking what Jeff has been focusing on since the Barcelona conference in May. Jeff de...